UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF

THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): March 18, 2013

 

 

SABRA HEALTH CARE REIT, INC.

(Exact name of registrant as specified in its charter)

 

 

 

Maryland		001-34950		27-2560479
(State of Incorporation)		(Commission File Number)		(I.R.S. Employer Identification No.)

 

18500 Von Karman Avenue, Suite 550 Irvine, CA		92612
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number including area code: (888) 393-8248

Not Applicable

(Former name or former address, if changed since last report.)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

---

Item 8.01

Other Events

On March 18, 2013, Sabra Health Care REIT, Inc. (the “Company”) entered into a sales agreement with each of Barclays Capital Inc., Cantor Fitzgerald & Co., Credit Agricole Securities (USA) Inc., RBC Capital Markets, LLC, RBS Securities Inc. and Wells Fargo Securities, LLC (individually, a “Sales Agent” and together, the “Sales Agents”) to sell shares of its common stock, $0.01 par value per share, having aggregate gross proceeds of up to $100,000,000 (the “Shares”) from time to time through the Sales Agents.

Pursuant to the terms of the sales agreements, the Shares may be sold by any method permitted by law deemed to be an “at-the-market” offering, including, without limitation, sales made directly on the NASDAQ Global Select Market, on any other existing trading market for the Company’s common stock or to or through a market maker. In addition, with the Company’s prior consent, the Sales Agents may also sell the Shares in privately negotiated transactions. The Company will pay each Sales Agent a commission equal to 2% of the gross proceeds from the sales of Shares sold pursuant to the applicable sales agreement. The offering of Shares pursuant to any sales agreement will terminate upon the earlier of (i) the sale of the maximum aggregate amount of the Shares subject to the sales agreements, or (ii) termination of such sales agreement as permitted therein.

The Company intends to contribute the net proceeds from the sales of Shares pursuant to the sales agreements to Sabra Health Care Limited Partnership (the “Operating Partnership”), which will in turn use the net proceeds to repay indebtedness, fund possible future acquisitions and/or for general corporate purposes. Indebtedness that may be repaid by the Operating Partnership includes borrowings that may then be outstanding under the Company’s amended secured revolving credit facility. Affiliates of Barclays Capital Inc., Credit Agricole Securities (USA) Inc., RBC Capital Markets, LLC, RBS Securities Inc. and Wells Fargo Securities, LLC are lenders under the Company’s amended secured revolving credit facility and, in such capacity, may receive a portion of the net proceeds from the offering of Shares pursuant to the sales agreements to the extent that the Company uses any net proceeds to reduce amounts outstanding under the facility. The Company or any of the Sales Agents may at any time suspend the offering or terminate the applicable sales agreement pursuant to the terms of such sales agreement.

The foregoing description of the material terms of the sales agreements and the transactions contemplated thereby does not purport to be complete and is qualified in its entirety by reference to the full text of the sales agreements, the form of which is filed as Exhibit 1.1 to this report and incorporated herein by reference. The sales agreements with the Sales Agents listed above are substantially identical in all material respects.

The Shares will be issued pursuant to the Company’s shelf registration statement on Form S-3 (File No. 333-177144) filed with the Securities and Exchange Commission (the “SEC”), which was declared effective on October 31, 2011, and the prospectus supplement filed by the Company with the SEC on March 18, 2013. This Current Report on Form 8-K does not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of Shares in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.

A copy of the opinion of Venable LLP, relating to the legality of the Shares, is filed as Exhibit 5.1 to this Current Report on Form 8-K and is incorporated herein by reference.

 

Item 9.01

Financial Statements and Exhibits.

 

(d)

Exhibits

 

1.1	Form of Sales Agreement, dated March 18, 2013, between the Company and each of Barclays Capital Inc., Cantor Fitzgerald & Co., Credit Agricole Securities (USA) Inc., RBC Capital Markets, LLC, RBS Securities Inc. and Wells Fargo Securities, LLC.

 

5.1	Opinion of Venable LLP.

 

23.1	Consent of Venable LLP (included in Exhibit 5.1).

---

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

Dated:  March 18, 2013

---

EXHIBIT INDEX

 

Exhibit No.		Description
1.1		Form of Sales Agreement, dated March 18, 2013, between the Company and each of Barclays Capital Inc., Cantor Fitzgerald & Co., Credit Agricole Securities (USA) Inc., RBC Capital Markets, LLC, RBS Securities Inc. and Wells Fargo Securities, LLC.
5.1		Opinion of Venable LLP.
23.1		Consent of Venable LLP (included in Exhibit 5.1).